Please assess the completion status of the following clinical trial:

Trial Title: An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects who have completed Study M13-550 (NCT01960855) or Study M13-537 (NCT02066389) with upadacitinib (ABT-494) and did not develop any discontinuation criteria.~2. If the subject has evidence of new latent tuberculosis (TB) infection, the subject must initiate and complete a minimum of 2 weeks (or per local guidelines, whichever is longer) of an ongoing TB prophylaxis before continuing to receive study drug.~3. If female, subject must be postmenopausal, OR permanently surgically sterile, OR for women of childbearing potential practicing at least one protocol-specified method of birth control, that is effective from Study Day 1 through at least 30 days after the last dose of study drug.~4. Subjects must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study specific procedures.~Substudy:~1. Must currently be enrolled in the main study.~2. Must have been receiving a stable dose of upadacitinib (either 15 mg QD or 30 mg QD) for a minimum of 4 weeks prior to the Vaccination visit.~3. Must have been on a stable dose of background methotrexate (no change in dose or frequency) for a minimum of 4 weeks prior to the Vaccination visit.~4. If subject is on corticosteroids, must remain on a stable dose of ≤ 10 mg/day of prednisone or equivalent corticosteroid therapy for at least 4 weeks after the vaccination visit.~5. Must meet the prescribing specifications as per local label requirements to receive Prevnar 13® vaccine.~6. Willing to receive Prevnar13® vaccine.~Exclusion Criteria:~1. Pregnant or breastfeeding female.~2. Ongoing infections at Week 0 that have not been successfully treated. Subjects with ongoing infections undergoing treatment may be enrolled but not dosed until the infection has been successfully treated.~3. Anticipated requirement or receipt of any live vaccine during study participation including up to 30 days after the last dose of study drug.~4. Laboratory values from the visit immediately prior to Baseline Visit (local requirements may apply) meeting the following criteria:~   * Serum aspartate transaminase (AST) or alanine transaminase (ALT) \> 3.0 × upper limit of normal (ULN)~  * Estimated glomerular filtration rate by simplified 4-variable Modification of Diet in Renal Disease (MDRD) formula \< 40 mL/min/1.73m\^2~  * Total white blood cell count (WBC) \< 2,000/μL~  * Absolute neutrophil count (ANC) \< 1,000/μL~  * Platelet count \< 50,000/μL~  * Absolute lymphocytes count \< 500/μL~  * Hemoglobin \< 8 g/dL~5. Enrollment in another interventional clinical study while participating in this study.~6. Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive study drug.~Substudy:~1. Receiving any conventional synthetic disease modifying antirheumatic drugs (csDMARDs) other than methotrexate~2. Receiving \> 10 mg/day of prednisone or equivalent corticosteroid therapy.~3. Receipt of any steroid injection within 4 weeks prior to Vaccination visit.~4. History of severe allergic reaction (e.g., anaphylaxis) to any component of Prevnar 13®.~5. History of any documented pneumococcal infection within the last 6 months prior to the vaccination visit.~6. Receipt of any vaccine 4 weeks prior to the vaccination visit and/or anticipation of any vaccination for 4 weeks after the vaccination visit.~7. Receipt of any pneumococcal vaccine.~8. Subject is not suitable for the sub-study as per the Investigator's judgment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Upadacitinib (Type: EXPERIMENTAL): Participants received treatment with upadacitinib for up to 312 weeks. The starting dose was 6 mg twice a day (BID). Participants who did not achieve a 20% improvement from RCT Baseline in both Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 6 or Week 12 were up-titrated to 12 mg BID. From January 2017 participants were transitioned to a once-daily (QD) regimen of upadacitinib, either 15 mg QD (participants who were taking 6 mg BID) or 30 mg QD (participants taking 12 mg BID). Starting with Protocol Amendment 5 participants receiving 30 mg QD upadacitinib had the option to decrease the dose to 15 mg QD at the investigator's discretion.~A subset of participants who opted-in to the vaccine substudy received a single-dose of 0.5 mL intramuscular injection of pneumococcal 13-valent conjugate vaccine (PCV-13).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete